Licopid® (GMDP) is one of immunomodulators with known and predictable effect, providing it a clear advantage.
Pharmacologic activity of drug is achieved by binding of its effective agent – GMDP with intracellular receptor of innate immunity NOD2 (Girardin S.E., 2003; Meshcheryakova E., 2007). GMDP binding with the receptor results in a series of intracellular events ending by activation of nuclear factor (NF) and production of a series of key cytokines— IL-1, IL-6, IL-12, TNF-α, interferon-gamma, and colony-stimulating factors (CSF).
By influence on key molecular target (receptor) in immune system, GMDP as part of Licopid imitates the natural discovery process of peptidoglycan fragments in bacteria.
Discovery of innate immunity receptors and description of the methods operation of innate immunity was awarded the Nobel Prize in Physiology and Medicine in 2011. Further information on main operating principles of innate immunity in view of modern representations could be found in article “Nobel Prize or Ode to Innate Immunity”.